TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

THI OBI

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: US

Quick snapshot

THI OBI

ST13

US500000098424308

Class

1, 5, 42, 44

Filing

98424308

Registration

8182708

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

27

Latest update

03/25/2026

Classification

Registered

Trademark type

Combined

Nice classes

1, 5, 42, 44

Filing date

02/27/2024

Registration date

03/24/2026

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

03/24/2026

Last transaction

03/25/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

Drawing code

3

Owner type

03

Owner location

Taipei City, TW

Examiner

OSBORNE, AUDRIANA R

Law office

L60

Current location

FILE REPOSITORY (FRANCONIA)

Mark description

The mark consists of The "Thi" is black, the "OBI" is teal. Below OBI is a teal underline.

Holders and representatives

Holders

OBI PHARMA, INC.

Representatives

Ran He

Technical classification

Nice Classes

Class 1Class 5Class 42Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 1

Carbide; Cellulose; Glycogen; Glycoprotein; Sulfides; Active chemical ingredients for use in the manufacture of anti-cancer drugs; Adjuvants, other than for medical or veterinary purposes; Antioxidants for use in the manufacture of pharmaceuticals; Biochemical catalysts; Biological preparations for use in industry and science; Carbonic hydrates; Chemical additives for use in the manufacture of pharmaceuticals; Chemical preparations for scientific purposes, other than for medical or veterinary use; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes; Fatty acids for use in pharmaceutical; Polymers and polymeric additives for use in the manufacture of pharmaceutical preparations, plastics, cosmetics, personal care products, coatings, adhesives, and lubricants; Protein in raw material form for scientific and medical research; Proteins for use in manufacture; Proteins for use in the manufacture of drugs

Class 5

Immunostimulants; Vaccines; Adjuvants for medical purposes; Anti-cancer preparations; Biological preparations for the treatment of cancer; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer to be prevented or treated; Chemical reagents for medical or veterinary purposes; Enzyme preparations for medical purposes; Enzymes for medical purposes; Ferments for pharmaceutical purposes; Hormones for medical purposes; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment and prevention of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Preparations of microorganisms for medical purposes; Tumor suppressing agents

Class 42

Biological research; Biological research and analysis; Chemical analysis; Chemical research; Chemical research and analysis; Chemical research services; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research; Medical research in the field of oncology; Medical research services; Medical research services in the field of cancer; Pharmaceutical research and development; Providing information about medical research in the field of cancer, oncology; Providing laboratory research services in the field of gene expression, namely, cancer biology; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Scientific laboratory services; Scientific research; Scientific research and development; Scientific research in the field of genetics; Technical research in the field of pharmaceutical studies

Class 44

Administering vaccines to patients; Alternative medicine services; Cancer screening services; Cultured cell bank services for medical transplantation; Health care; Health care services for treating cancer; Health assessment services; Health counselling; Human tissue bank services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical assistance; Medical screening; Medical treatment using cultured cells; Nursing, medical; Occupational therapy; Providing health information in the field of cancer prevention and treatment; Providing information in the field of cancer prevention, screening, diagnosis and treatment; Regenerative medicine services; Remote monitoring of medical data for medical diagnosis and treatment; Telemedicine services

Publications

History of USPTO decisions and trademark events.

27 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

03/24/2026

R.PR

REGISTERED-PRINCIPAL REGISTER

03/24/2026

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

02/03/2026

PUBO

PUBLISHED FOR OPPOSITION

02/03/2026

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

01/28/2026

OTHE

CASE RETURNED TO EXAMINATION

10/27/2025

IUCN

NOTICE OF ALLOWANCE CANCELLED

10/27/2025

PCBG

PETITION TO DIRECTOR - CHANGE BASIS - GRANTED

10/27/2025

APET

ASSIGNED TO PETITION STAFF

10/22/2025

TPAD

TEAS PETITION TO AMEND BASIS RECEIVED

09/22/2025

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

03/03/2025

EX1G

SOU EXTENSION 1 GRANTED

12/17/2024

EXT1

SOU EXTENSION 1 FILED

12/16/2024

EEXT

SOU TEAS EXTENSION RECEIVED

12/16/2024

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

10/01/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

08/06/2024

PUBO

PUBLISHED FOR OPPOSITION

08/06/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

07/17/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

06/27/2024

XAEC

EXAMINER'S AMENDMENT ENTERED

06/27/2024

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

06/27/2024

GNEA

EXAMINERS AMENDMENT E-MAILED

06/27/2024

CNEA

EXAMINERS AMENDMENT -WRITTEN

06/27/2024

DOCK

ASSIGNED TO EXAMINER

06/26/2024

MDSC

NOTICE OF DESIGN SEARCH CODE E-MAILED

04/04/2024

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

04/03/2024

NWAP

NEW APPLICATION ENTERED

03/01/2024

Continuous trademark protection

Get notified about every new filing that threatens THI OBI or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.